RWA
SRNE

Ropes Wealth Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Ropes Wealth Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,600
Closed -$23K – 671
2020
Q2 		$23K Buy
+3,600
New +$13.8K ﹤0.01% 382

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ropes Wealth Advisors's SRNE Position: Q3 2020 in Review

Ropes Wealth Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 3,600 shares — an estimated $23K sold.

Ropes Wealth Advisors first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $23K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Ropes Wealth Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Ropes Wealth Advisors sold 3,600 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $23K.
  • Ropes Wealth Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Ropes Wealth Advisors's Sorrento Therapeutics, Inc. position peaked at $23K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Ropes Wealth Advisors's 13F filing for Q3 2020, filed 16 Oct 2020.